Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6795719 | 0.99 | EGFR (0.59) | EGFREPHA2 | |
| SCHEMBL6789014 | 0.91 | EGFR (0.66) | EGFR | |
| SCHEMBL26750138 | 0.91 | EGFR (0.53) | EGFR | |
| Hydrochloric Acid SCHEMBL6789311 | 0.90 | EGFR (0.65) | EGFR | |
| SCHEMBL6790158 | 0.90 | EGFR (0.57) | EGFR | |
| Hydrochloric Acid SCHEMBL6800792 | 0.89 | EGFR (0.56) | EGFR | |
| SCHEMBL24328905 | 0.85 | EGFR (0.61) | EGFREPHA2 | |
| SCHEMBL24328788 | 0.85 | EGFR (0.61) | EGFREPHA2 | |
| SCHEMBL24328630 | 0.85 | EGFR (0.61) | EGFREPHA2 | |
| SCHEMBL24328807 | 0.85 | EGFR (0.61) | EGFREPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835735-B2 | Anticancer, tyrosine kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-12-28 | — | — | US | claimed |
| US-20030045537-A1 | 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same | KOREAN INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2003-03-06 | — | — | US | claimed |
| WO-2024081447-A1 | EGFR INHIBITORS FOR TREATING LUNG CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | disclosed |
| US-20230358726-A1 | NON-INVASIVE FUNCTIONAL COMPANION ASSAYS FOR ONCOGENE TARGETED THERAPY FOR BRAIN CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-09 | — | — | US | disclosed |
| US-11377451-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
| US-6835735-B2 | Anticancer, tyrosine kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-12-28 | — | — | US | disclosed |
| US-20030045537-A1 | 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same | KOREAN INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377451-B2 | Compositions and methods for treating cancer | TP53, EGFR, SLC2A1 | EGFR 2/4885EPHA2 175/4885 |
| US-20030045537-A1 | 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same | EGFR, ERBB2, ERBB4 | EGFR 1/4885EPHA2 228/4885 |
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, EGFR, SLC2A1 | EGFR 2/4885EPHA2 128/4885 |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, SLC2A1, EGFR | EGFR 3/4885EPHA2 143/4885 |
| US-20230358726-A1 | NON-INVASIVE FUNCTIONAL COMPANION ASSAYS FOR ONCOGENE TARGETED THERAPY FOR BRAIN CANCER | EGFR, IDH1, KRAS | EGFR 1/4885EPHA2 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.